SG10201604560TA - Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition - Google Patents
Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix depositionInfo
- Publication number
- SG10201604560TA SG10201604560TA SG10201604560TA SG10201604560TA SG10201604560TA SG 10201604560T A SG10201604560T A SG 10201604560TA SG 10201604560T A SG10201604560T A SG 10201604560TA SG 10201604560T A SG10201604560T A SG 10201604560TA SG 10201604560T A SG10201604560T A SG 10201604560TA
- Authority
- SG
- Singapore
- Prior art keywords
- compositions
- preventing
- conditions
- methods
- extracellular matrix
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161474370P | 2011-04-12 | 2011-04-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201604560TA true SG10201604560TA (en) | 2016-07-28 |
Family
ID=47006527
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201604560TA SG10201604560TA (en) | 2011-04-12 | 2012-04-12 | Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition |
| SG2013075031A SG194135A1 (en) | 2011-04-12 | 2012-04-12 | Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG2013075031A SG194135A1 (en) | 2011-04-12 | 2012-04-12 | Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US9642888B2 (en) |
| EP (1) | EP2696888B1 (en) |
| JP (1) | JP6031510B2 (en) |
| KR (1) | KR101862291B1 (en) |
| CN (3) | CN108014340A (en) |
| AU (1) | AU2012242768B2 (en) |
| BR (1) | BR112013026313A8 (en) |
| CA (2) | CA2832910C (en) |
| DK (1) | DK2696888T3 (en) |
| ES (1) | ES2711670T3 (en) |
| HK (1) | HK1255005A1 (en) |
| MX (1) | MX359516B (en) |
| RU (1) | RU2620066C2 (en) |
| SG (2) | SG10201604560TA (en) |
| WO (1) | WO2012142320A2 (en) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2594281T3 (en) | 2007-01-10 | 2016-12-19 | Purdue Research Foundation | HSP27 kinase polypeptide inhibitors and uses thereof |
| WO2009021137A2 (en) | 2007-08-07 | 2009-02-12 | Purdue Research Foundation | Kinase inhibitors and uses thereof |
| AU2009324661A1 (en) * | 2008-12-10 | 2011-07-07 | Purdue Research Foundation | Cell-permeant peptide-based inhibitor of kinases |
| US9890195B2 (en) * | 2009-07-27 | 2018-02-13 | Purdue Research Foundation | MK2 inhibitor compositions and methods to enhance neurite outgrowth, neuroprotection, and nerve regeneration |
| EP2575855A4 (en) * | 2010-05-24 | 2014-03-12 | Moerae Matrix Inc | Methods for treating or preventing vascular graft failure |
| US9642888B2 (en) | 2011-04-12 | 2017-05-09 | Moerae Matrix, Inc. | Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition |
| US9890200B2 (en) | 2011-04-12 | 2018-02-13 | Moerae Matrix, Inc. | Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition |
| FR2976587B1 (en) * | 2011-06-20 | 2015-04-03 | Basf Beauty Care Solutions F | IN VITRO DOSING METHOD BY IMMUNOLOGICAL TECHNIQUE |
| WO2013134636A1 (en) | 2012-03-09 | 2013-09-12 | Purdue Research Foundation | Compositions and methods for delivery of kinase inhibiting peptides |
| CA2884802A1 (en) * | 2012-10-31 | 2014-05-08 | Galecto Biotech Ab | Galactoside inhibitor of galectin-3 and its use for treating pulmonary fibrosis |
| US9757529B2 (en) | 2012-12-20 | 2017-09-12 | Otitopic Inc. | Dry powder inhaler and methods of use |
| US9757395B2 (en) | 2012-12-20 | 2017-09-12 | Otitopic Inc. | Dry powder inhaler and methods of use |
| ES2864862T3 (en) | 2013-03-12 | 2021-10-14 | Celltaxis Llc | Leukotriene A4 hydrolase inhibition methods |
| KR20150127245A (en) | 2013-03-14 | 2015-11-16 | 켈탁시스, 인코퍼레이티드 | Inhibitors of leukotriene a4 hydrolase |
| US10149823B2 (en) | 2013-04-30 | 2018-12-11 | Otitopic Inc. | Dry powder formulations and methods of use |
| MX2016011852A (en) * | 2014-03-14 | 2017-05-09 | Moerae Matrix Inc | Compositions and methods for preventing or treating chronic lung allograft dysfunction and idiopathic pulmonary fibrosis. |
| US10336788B2 (en) * | 2014-04-17 | 2019-07-02 | Moerae Matrix, Inc. | Inhibition of cardiac fibrosis in myocardial infarction |
| AU2015350151A1 (en) * | 2014-11-17 | 2017-06-01 | Moerae Matrix, Inc. | Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition |
| KR20170102900A (en) | 2015-01-08 | 2017-09-12 | 모레 매트릭스 인코포레이티드 | Formulation of MK2 inhibitor peptide |
| CN107921082A (en) | 2015-03-12 | 2018-04-17 | 莫伊莱麦屈克斯公司 | Composition containing MK2 inhibitor peptides is used for the purposes for treating non-small cell lung cancer |
| US10195147B1 (en) | 2017-09-22 | 2019-02-05 | Otitopic Inc. | Dry powder compositions with magnesium stearate |
| US10786456B2 (en) | 2017-09-22 | 2020-09-29 | Otitopic Inc. | Inhaled aspirin and magnesium to treat inflammation |
| CN107987128B (en) * | 2017-11-17 | 2019-06-11 | 广东医科大学 | A kind of functional polypeptide and its application in preparation prevention and treatment pulmonary fibrosis medicine |
| US20210212988A1 (en) * | 2018-05-17 | 2021-07-15 | Actuate Therapeutics Inc. | Treatment of idiopathic pulmonary fibrosis with glycogen synthase kinase 3 form beta inhibitors |
| EP3801559A4 (en) | 2018-05-31 | 2022-03-02 | Celltaxis, LLC | Method of reducing pulmonary exacerbations in respiratory disease patients |
| CN110108883A (en) * | 2018-10-27 | 2019-08-09 | 广州呼吸健康研究院 | It is combined for screening with the marker of the accurate medicine of MSC of target treatment ARDS patient |
| CN109406795A (en) * | 2018-11-20 | 2019-03-01 | 昆明医科大学 | A kind of serum molecules diagnostic marker of light-duty brain trauma and application |
| WO2021040673A1 (en) * | 2019-08-26 | 2021-03-04 | Alain Martin | Methods for the treatment of chronic hypoxemia and inhibiting lung fibrosis in patients with pulmonary fibrosis with and without copd |
| USD958124S1 (en) | 2019-12-16 | 2022-07-19 | Samsung Electronics Co., Ltd. | Television receiver |
| USD978094S1 (en) | 2019-12-27 | 2023-02-14 | Samsung Electronics Co., Ltd. | Television receiver |
| WO2021146662A1 (en) * | 2020-01-17 | 2021-07-22 | Muhammed Majeed | Therapeutic compositions and methods for pulmonary fibrosis |
| CN112386682B (en) * | 2020-02-12 | 2022-12-06 | 王斌 | Application of fibronectin in preparing medicine for treating novel coronavirus pneumonia |
| US20230127499A1 (en) * | 2020-03-30 | 2023-04-27 | Figene, Llc | Peptides and adjuvants for augmentation of fibroblast therapy for coronavirus |
| US20230141224A1 (en) * | 2020-04-01 | 2023-05-11 | Figene, Llc | Fibroblast mediated expansion and augmentation of immune regulatory cells for treatment of acute respiratory distress syndrome (ards) |
| JP2023522921A (en) * | 2020-04-21 | 2023-06-01 | リモデレス シーヴイ リミテッド | A novel treatment for acute injury to lung tissue |
| AU2021390125A1 (en) * | 2020-12-03 | 2023-06-22 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Pharmaceutical composition comprising anti-connective tissue growth factor antibody |
| USD989726S1 (en) | 2020-12-03 | 2023-06-20 | Samsung Electronics Co., Ltd. | Television receiver |
| USD989017S1 (en) | 2020-12-03 | 2023-06-13 | Samsung Electronics Co., Ltd. | Television receiver |
| WO2022147172A1 (en) * | 2020-12-30 | 2022-07-07 | Briotech, Inc. | Methods and compositions of aqueous hypobromous acid for the treatment and prevention of inflammatory conditions |
| WO2022204045A1 (en) * | 2021-03-22 | 2022-09-29 | Spiritus Therapeutics, Inc. | Diagnostic and therapeutic uses of purified potent exosomes containing disease-based and therapy based signature cargo |
| CN113440431A (en) * | 2021-08-02 | 2021-09-28 | 山西锦波生物医药股份有限公司 | Application of recombinant III-type humanized collagen in scalp care and scalp care product containing same |
| WO2023178169A2 (en) * | 2022-03-15 | 2023-09-21 | Anemoi Biotech Holdings, Inc. | Compositions and methods for treating the pathophysiology of severe viral infection |
| CN116789751B (en) * | 2023-08-22 | 2023-11-17 | 中国农业大学 | Polypeptide for preventing and/or treating fibrosis diseases and application thereof |
| CN117577330B (en) * | 2024-01-15 | 2024-04-02 | 北京大学 | Device and storage medium for predicting liver fibrosis degree of nonalcoholic fatty liver disease |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1521000A (en) | 1975-06-13 | 1978-08-09 | Syntex Puerto Rico Inc | Inhalation device |
| US4227522A (en) | 1978-09-05 | 1980-10-14 | Syntex Puerto Rico, Inc. | Inhalation device |
| US4192309A (en) | 1978-09-05 | 1980-03-11 | Syntex Puerto Rico, Inc. | Inhalation device with capsule opener |
| ES286422Y (en) | 1982-10-08 | 1986-09-16 | Glaxo Group Limited | DEVICE FOR ADMINISTERING MEDICINES TO PATIENTS |
| US4778054A (en) | 1982-10-08 | 1988-10-18 | Glaxo Group Limited | Pack for administering medicaments to patients |
| AU591152B2 (en) | 1985-07-30 | 1989-11-30 | Glaxo Group Limited | Devices for administering medicaments to patients |
| JPH05963A (en) | 1990-04-13 | 1993-01-08 | Toray Ind Inc | Polypeptide composition |
| US6331318B1 (en) | 1994-09-30 | 2001-12-18 | Emisphere Technologies Inc. | Carbon-substituted diketopiperazine delivery systems |
| US5352461A (en) | 1992-03-11 | 1994-10-04 | Pharmaceutical Discovery Corporation | Self assembling diketopiperazine drug delivery system |
| WO1993022443A1 (en) | 1992-04-24 | 1993-11-11 | Sri International | In vivo homologous sequence targeting in eukaryotic cells |
| US6582728B1 (en) | 1992-07-08 | 2003-06-24 | Inhale Therapeutic Systems, Inc. | Spray drying of macromolecules to produce inhaleable dry powders |
| EP0733059B1 (en) | 1993-12-09 | 2000-09-13 | Thomas Jefferson University | Compounds and methods for site-directed mutations in eukaryotic cells |
| US6428771B1 (en) | 1995-05-15 | 2002-08-06 | Pharmaceutical Discovery Corporation | Method for drug delivery to the pulmonary system |
| JP2002540850A (en) | 1999-04-05 | 2002-12-03 | ファーマシューティカル ディスカバリー コーポレイション | Method for fine powder formation |
| DK1808438T3 (en) | 1999-06-29 | 2014-10-27 | Mannkind Corp | Purification and stabilization of peptide and proteins in drugs |
| NZ536796A (en) * | 2002-04-25 | 2007-03-30 | Scripps Research Inst | Treatment and prevention of pulmonary conditions comprising at least one lung surfactant polypeptide and at least one protease inhibitor, lipase inhibitor or an anti-oxidant |
| US20040219142A1 (en) * | 2002-07-19 | 2004-11-04 | Abbott Laboratories S.A. | Treatment of skin and nail disorders using TNFalpha inhibitors |
| EP2260718B1 (en) * | 2003-11-25 | 2014-10-22 | Virginia Tech Intellectual Properties, Inc. | Composition for animal consumption for use in reducing MAP kinase activity |
| EP1753428A4 (en) * | 2004-05-14 | 2010-09-15 | Abbott Lab | Kinase inhibitors as therapeutic agents |
| EP1786784B1 (en) | 2004-08-20 | 2010-10-27 | MannKind Corporation | Catalysis of diketopiperazine synthesis |
| WO2006023944A2 (en) | 2004-08-23 | 2006-03-02 | Mannkind Corporation | Pulmonary delivery of inhibitors of phosphodiesterase type 5 |
| DK2322180T3 (en) | 2004-08-23 | 2015-06-15 | Mannkind Corp | Diketopiperazinsalte for drug delivery |
| CN101227918A (en) * | 2005-04-29 | 2008-07-23 | 加州大学评议会 | Peptides and peptide simulacrums to treat pathologies characterized by an inflammatory response |
| KR101643478B1 (en) | 2005-09-14 | 2016-07-27 | 맨카인드 코포레이션 | Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents |
| MX360812B (en) | 2006-02-22 | 2018-11-16 | Mannkind Corp | A method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent. |
| MX2008012794A (en) * | 2006-04-03 | 2008-10-15 | Teva Pharma | Drug microparticles. |
| ES2594281T3 (en) | 2007-01-10 | 2016-12-19 | Purdue Research Foundation | HSP27 kinase polypeptide inhibitors and uses thereof |
| WO2008098096A1 (en) | 2007-02-08 | 2008-08-14 | Boehringer Ingelheim International Gmbh | Anti-cytokine heterocyclic compounds |
| US20080282320A1 (en) | 2007-05-11 | 2008-11-13 | Denovo Andrew | Security Compliance Methodology and Tool |
| WO2009021137A2 (en) | 2007-08-07 | 2009-02-12 | Purdue Research Foundation | Kinase inhibitors and uses thereof |
| WO2009085191A2 (en) | 2007-12-21 | 2009-07-09 | Cabot Corporation | Syntactic foam compositions, pipelines insulated with same, and method |
| DK2349310T3 (en) * | 2008-10-20 | 2014-08-11 | Moerae Matrix Inc | POLYPEPTIME FOR TREATMENT OR PREVENTION OF ADHESIONS |
| AU2009324661A1 (en) * | 2008-12-10 | 2011-07-07 | Purdue Research Foundation | Cell-permeant peptide-based inhibitor of kinases |
| EP2575855A4 (en) | 2010-05-24 | 2014-03-12 | Moerae Matrix Inc | Methods for treating or preventing vascular graft failure |
| US9642888B2 (en) | 2011-04-12 | 2017-05-09 | Moerae Matrix, Inc. | Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition |
-
2012
- 2012-04-12 US US13/445,759 patent/US9642888B2/en not_active Expired - Fee Related
- 2012-04-12 JP JP2014505291A patent/JP6031510B2/en not_active Expired - Fee Related
- 2012-04-12 AU AU2012242768A patent/AU2012242768B2/en not_active Ceased
- 2012-04-12 BR BR112013026313A patent/BR112013026313A8/en not_active Application Discontinuation
- 2012-04-12 ES ES12771584T patent/ES2711670T3/en active Active
- 2012-04-12 DK DK12771584.5T patent/DK2696888T3/en active
- 2012-04-12 SG SG10201604560TA patent/SG10201604560TA/en unknown
- 2012-04-12 CA CA2832910A patent/CA2832910C/en not_active Expired - Fee Related
- 2012-04-12 CN CN201711403446.9A patent/CN108014340A/en active Pending
- 2012-04-12 CN CN201280027012.2A patent/CN104302310A/en active Pending
- 2012-04-12 CN CN201910892185.4A patent/CN111110850A/en active Pending
- 2012-04-12 MX MX2013011771A patent/MX359516B/en active IP Right Grant
- 2012-04-12 RU RU2013150249A patent/RU2620066C2/en not_active IP Right Cessation
- 2012-04-12 EP EP12771584.5A patent/EP2696888B1/en not_active Not-in-force
- 2012-04-12 SG SG2013075031A patent/SG194135A1/en unknown
- 2012-04-12 CA CA3042808A patent/CA3042808A1/en not_active Abandoned
- 2012-04-12 KR KR1020137029996A patent/KR101862291B1/en active IP Right Grant
- 2012-04-12 WO PCT/US2012/033368 patent/WO2012142320A2/en active Application Filing
-
2017
- 2017-04-04 US US15/478,950 patent/US20190022169A1/en not_active Abandoned
-
2018
- 2018-11-06 HK HK18114121.3A patent/HK1255005A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3042808A1 (en) | 2012-10-18 |
| CN104302310A (en) | 2015-01-21 |
| BR112013026313A2 (en) | 2016-12-27 |
| US20190022169A1 (en) | 2019-01-24 |
| AU2012242768A1 (en) | 2013-10-24 |
| MX2013011771A (en) | 2014-07-30 |
| KR20140063517A (en) | 2014-05-27 |
| BR112013026313A8 (en) | 2018-01-30 |
| RU2620066C2 (en) | 2017-05-22 |
| EP2696888B1 (en) | 2018-12-05 |
| MX359516B (en) | 2018-10-01 |
| CN111110850A (en) | 2020-05-08 |
| US20120263680A1 (en) | 2012-10-18 |
| AU2012242768B2 (en) | 2017-10-12 |
| CA2832910C (en) | 2019-07-02 |
| US9642888B2 (en) | 2017-05-09 |
| WO2012142320A2 (en) | 2012-10-18 |
| JP2014533235A (en) | 2014-12-11 |
| ES2711670T3 (en) | 2019-05-06 |
| SG194135A1 (en) | 2013-11-29 |
| WO2012142320A8 (en) | 2014-02-20 |
| NZ616672A (en) | 2016-04-29 |
| DK2696888T3 (en) | 2019-03-25 |
| JP6031510B2 (en) | 2016-11-24 |
| RU2013150249A (en) | 2015-05-20 |
| EP2696888A2 (en) | 2014-02-19 |
| EP2696888A4 (en) | 2016-04-20 |
| HK1255005A1 (en) | 2019-08-02 |
| CN108014340A (en) | 2018-05-11 |
| WO2012142320A3 (en) | 2015-06-11 |
| CA2832910A1 (en) | 2012-10-18 |
| KR101862291B1 (en) | 2018-05-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1255005A1 (en) | Compositions and methods for preventing or treating diseases characterized by aberrant fibroblast proliferation and extracellular matrix deposition | |
| PL2672966T3 (en) | Pharmaceutical composition, methods for treating and uses thereof | |
| ZA201703305B (en) | Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition | |
| HUE056081T2 (en) | Seed coatings, coating compositions and methods for use | |
| HUE054621T2 (en) | Pharmaceutical composition, methods for treating and uses thereof | |
| HK1170490A1 (en) | Pharmaceutical composition for treating or preventing glaucoma | |
| EP2576488A4 (en) | Process for cis-1,1,1,4,4,4,-hexafluoro-2-butene | |
| ZA201308918B (en) | Multiple myeloma treatment | |
| EP2729156A4 (en) | Methods and compositions useful for treating fitzpatrick type iv, v or vi skin | |
| EP2688402A4 (en) | Methods for treating or preventing urological inflammation | |
| PT2770979E (en) | Improved cross-linking composition delivered by iontophoresis, useful for the treatment of keratoconus | |
| HK1207579A1 (en) | Composition for preventing or treating heart disease | |
| SG11201701135WA (en) | Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition | |
| EP2748297A4 (en) | Improvements relating to polymers, deposition aids, targeted benefit agents and substrate treatment compositions | |
| EP2673305A4 (en) | Ziegler-natta catalyst composition with controlled morphology | |
| EP2872166A4 (en) | Compositions and methods for detecting, treating and preventing diseases and disorders | |
| HK1200364A1 (en) | Topical film-forming composition and use thereof for treating or preventing onychophagia | |
| ZA201309630B (en) | Film-forming composition, and use thereof for treating herpes | |
| EP2691104A4 (en) | Ezatiostat for treating multiple myeloma | |
| SG11201501289TA (en) | Preparation for preventing or treating type i diabetes | |
| AU2011903969A0 (en) | Compositions for treating skin conditions | |
| IL213610A0 (en) | Composition for treating dermatological conditions | |
| GB201110653D0 (en) | Composition for skin treatment | |
| GB201110659D0 (en) | composition for skin treatment |